Virologic response to bictegravir/emtricitabine/tenofovir alafenamide in people with advanced HIV-1 disease: A propensity-weighted multicentre cohort study
Virologic response to bictegravir/emtricitabine/tenofovir alafenamide in people with advanced HIV-1 disease: A propensity-weighted multicentre cohort study. // International Journal of Antimicrobial Agents. – URL: https://www.sciencedirect.com/science/article/pii/S0924857926003079?dgcid=rss_sd_all
Virologic response to bictegravir/emtricitabine/tenofovir alafenamide in people with advanced HIV-1 disease: A propensity-weighted multicentre cohort study. International Journal of Antimicrobial Agents. https://www.sciencedirect.com/science/article/pii/S0924857926003079?dgcid=rss_sd_all
“Virologic response to bictegravir/emtricitabine/tenofovir alafenamide in people with advanced HIV-1 disease: A propensity-weighted multicentre cohort study.” International Journal of Antimicrobial Agents.
@article{article49457,
title = {Virologic response to bictegravir/emtricitabine/tenofovir alafenamide in people with advanced HIV-1 disease: A propensity-weighted multicentre cohort study},
journal = {International Journal of Antimicrobial Agents},
url = {https://www.sciencedirect.com/science/article/pii/S0924857926003079?dgcid=rss_sd_all}
}